Carsten Rose
About
Carsten Rose is a scholar working on Oncology, Cancer Research and Genetics.
According to data from OpenAlex, Carsten Rose has authored 115 papers receiving a total of 7.2k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Oncology, 49 papers in Cancer Research and 40 papers in Genetics. Recurrent topics in Carsten Rose's work include Breast Cancer Treatment Studies (44 papers), Estrogen and related hormone effects (37 papers) and Cancer Treatment and Pharmacology (32 papers). Carsten Rose is often cited by papers focused on Breast Cancer Treatment Studies (44 papers), Estrogen and related hormone effects (37 papers) and Cancer Treatment and Pharmacology (32 papers). Carsten Rose collaborates with scholars based in Denmark, Sweden and Germany. Carsten Rose's co-authors include Henning T. Mouridsen, Marie Overgaard, Michael Kjær, Jens Overgaard, Maj‐Britt Jensen, C. Gadeberg, Per Syrak Hansen, Karin Zedeler, Birgitte Rasmussen and Michael Andersson and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.
In The Last Decade
Carsten Rose
114 papers receiving 6.8k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Carsten Rose Denmark | 38 | 4.6k | 3.1k | 2.0k | 1.7k | 1.0k | 115 | 7.2k | ||
| Henry R. Shibata Canada | 23 | 3.8k 0.8× | 3.0k 1.0× | 2.0k 1.0× | 1.5k 0.9× | 620 0.6× | 45 | 6.0k | ||
| John H. Glick United States | 43 | 3.1k 0.7× | 5.8k 1.9× | 3.1k 1.5× | 1.2k 0.7× | 904 0.9× | 113 | 9.7k | ||
| R Poisson Canada | 15 | 3.9k 0.8× | 2.8k 0.9× | 2.0k 1.0× | 1.4k 0.8× | 1.0k 1.0× | 24 | 6.0k | ||
| Samuel Hellmän United States | 57 | 3.8k 0.8× | 3.8k 1.2× | 2.8k 1.4× | 2.1k 1.3× | 805 0.8× | 238 | 10.8k | ||
| Constance Cirrincione United States | 38 | 4.7k 1.0× | 6.8k 2.2× | 1.6k 0.8× | 750 0.4× | 810 0.8× | 81 | 9.8k | ||
| Isabelle Bedrosian United States | 54 | 5.8k 1.3× | 4.0k 1.3× | 3.5k 1.7× | 2.7k 1.6× | 1.2k 1.1× | 238 | 9.3k | ||
| Steven E. Come United States | 44 | 2.6k 0.6× | 3.9k 1.3× | 1.2k 0.6× | 870 0.5× | 1.2k 1.1× | 166 | 6.7k | ||
| Gordon F. Schwartz United States | 40 | 3.6k 0.8× | 1.9k 0.6× | 2.7k 1.3× | 1.2k 0.7× | 487 0.5× | 125 | 5.3k | ||
| Tari A. King United States | 48 | 5.6k 1.2× | 3.9k 1.3× | 3.0k 1.5× | 2.1k 1.3× | 1.2k 1.2× | 288 | 9.4k | ||
| Virgilio Sacchini United States | 47 | 6.7k 1.5× | 3.0k 1.0× | 4.3k 2.1× | 4.3k 2.6× | 1.5k 1.4× | 138 | 9.6k |
Countries citing papers authored by Carsten Rose
Since
Specialization
Citations
This map shows the geographic impact of Carsten Rose's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carsten Rose with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carsten Rose more than expected).
Fields of papers citing papers by Carsten Rose
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Carsten Rose. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carsten Rose. The network helps show where Carsten Rose may publish in the future.
Co-authorship network of co-authors of Carsten Rose
This figure shows the co-authorship network connecting the top 25 collaborators of Carsten Rose. A scholar is included among the top collaborators of Carsten Rose based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carsten Rose. Carsten Rose is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Borgquist, Signe, Magnus Simonsson, Andrea Markkula, et al.. (2014). Androgen Receptor Expression in a Population-Based Prospective Breast Cancer Cohort. Annals of Oncology. 25. i18–i18.
2.
Beex, L.V.A.M., Carsten Rose, H.T. Mouridsen, et al.. (2006). Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: An EORTC phase III study (10863). European Journal of Cancer. 42(18). 3178–3185.
3.
Rose, Carsten, Claus Kamby, Henning T. Mouridsen, et al.. (2000). Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer; A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age. Breast Cancer Research and Treatment. 61(2). 103–110.
4.
Overgaard, Marie, Maj‐Britt Jensen, Jens Overgaard, et al.. (1999). Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. The Lancet. 353(9165). 1641–1648.
5.
Andersson, Michael, Claus Kamby, Maj‐Britt Jensen, et al.. (1999). Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer Co-operative Group DBCG 82B trial. European Journal of Cancer. 35(12). 1659–1666.
6.
Andersson, Michael, Ebbe Lindegaard Madsen, Marie Overgaard, et al.. (1999). Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer—a randomised study with more than 10 years follow-up from the danish breast cancer cooperative group. European Journal of Cancer. 35(1). 39–46.
7.
Knoop, Ann, P.A. Andreasen, Steinbjørn Hansen, et al.. (1998). Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. British Journal of Cancer. 77(6). 932–940.
8.
Gerdes, Anne‐Marie, Ole Nielsen, Per Pfeiffer, et al.. (1998). Correlation between molecular genetic analyses and immunohistochemical evaluation of the epidermal growth factor receptor and p185HER2.. PubMed. 18(4A). 2529–34.
9.
Rose, Carsten. (1996). Proper Sequence of Endocrine Therapies in Advanced Breast Cancer. Acta Oncologica. 35(sup5). 44–49.
10.
Pfeiffer, Per, et al.. (1996). Concurrent Tamoxifen (TAM) + Cyclophosphamide, Epirubicin, and Fluorouracil (CEF) Versus Tam + Delayed Cef After Six Months of Endocrine Therapy in Metastatic Breast Cancer a Randomized Trial from the Danish Breast Cancer Cooperative Group (DBCG). Acta Oncologica. 35(sup5). 57–57.
11.
Pfeiffer, Per, Jens Ahm Sørensen, & Carsten Rose. (1995). Is carboplatin and oral etoposide an effective and feasible regimen in patients with small cell lung cancer?. European Journal of Cancer. 31(1). 64–69.
12.
Rose, Carsten, Michael Kjær, C. Boni, et al.. (1995). 352 An open, comparative randomized trial comparing formestane vs oral megestrol acetate as a second-line therapy in postmenopausal advanced breast cancer patients. European Journal of Cancer. 31. S76–S76.
13.
Balslev, I., Ib Jarle Christensen, Birgitte Rasmussen, et al.. (1994). Flow cytometric DNA ploidy defines patients with poor prognosis in node‐negative breast cancer. International Journal of Cancer. 56(1). 16–25.
14.
Pfeiffer, Per, et al.. (1993). Radiation-induced brachial plexopathy: Neurological follow-up in 161 recurrence-free breast cancer patients. International Journal of Radiation Oncology*Biology*Physics. 26(1). 43–49.
15.
Kamby, Claus, Johan A. Andersen, Bent Ejlertsen, et al.. (1991). Pattern of Spread and Progression in Relation to the Characteristics of the Primary Tumour in Human Breast Cancer. Acta Oncologica. 30(3). 301–308.
16.
Pfeiffer, Per, Olfred Hansen, & Carsten Rose. (1990). Systemic cytotoxic therapy of basal cell carcinoma. European Journal of Cancer and Clinical Oncology. 26(1). 73–77.
17.
Andersen, Jørn, Susan M. Thorpe, William King, et al.. (1990). The prognostic value of immunohistochemical estrogen receptor analysis in paraffin-embedded and frozen sections versus that of steroid-binding assays. European Journal of Cancer and Clinical Oncology. 26(4). 442–449.
18.
Kamby, Claus, Bent Ejlertsen, J. Andersen, et al.. (1988). The Pattern of Metastases in Human Breast Cancer Influence of systemic adjuvant therapy and impact on survival. Acta Oncologica. 27(6). 715–719.
19.
Kamby, Claus, Carsten Rose, Bent Ejlertsen, et al.. (1987). Stage and pattern of metastases in patients with breast cancer. European Journal of Cancer and Clinical Oncology. 23(12). 1925–1934.
20.
Ht, Mouridsen, et al.. (1980). Therapeutic effect of tamoxifen versus combined tamoxifen and diethylstilboestrol in advanced breast cancer in postmenopausal women.. PubMed. Suppl 1. 107–10.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Henry R. Shibata Breakdown of academic impact, for papers by John H. Glick Breakdown of academic impact, for papers by R Poisson Breakdown of academic impact, for papers by Samuel Hellmän Breakdown of academic impact, for papers by Constance Cirrincione Breakdown of academic impact, for papers by Isabelle Bedrosian Breakdown of academic impact, for papers by Steven E. Come Breakdown of academic impact, for papers by Gordon F. Schwartz Breakdown of academic impact, for papers by Tari A. King Breakdown of academic impact, for papers by Virgilio Sacchini